Sylvia Herter, Frank Herting, Gunter Muth, Erwin van Puijenbroek, Tilman Schlothauer, Claudia Ferrara, Kevin Brady, Sabine Lang, Marina Bacac, Ekkehard Mössner, Pablo Umana, and Christian Klein. 2018. “GA101 P329GLALA, a Variant of Obinutuzumab With Abolished ADCC, ADCP and CDC Function But Retained Cell Death Induction, Is As Efficient As Rituximab in B-Cell Depletion and Antitumor Activity”. Haematologica 103 (2). Pavia, Italy, e78-e81. https://doi.org/10.3324/haematol.2017.178996.